Atea Pharmaceuticals, Inc.
AVIR
$5.27
-$0.41-7.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 51.85% | 71.30% | 19.89% | 1.41% | -12.08% |
| Gross Profit | -51.85% | -71.30% | -19.89% | -1.41% | 12.08% |
| SG&A Expenses | -34.40% | -34.28% | -32.73% | -16.84% | -11.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.33% | 36.32% | 4.86% | -3.78% | -11.95% |
| Operating Income | -26.33% | -36.32% | -4.86% | 3.78% | 11.95% |
| Income Before Tax | -27.00% | -26.87% | 1.76% | 15.47% | 22.68% |
| Income Tax Expenses | -854.70% | -804.01% | -766.16% | -20.78% | -17.53% |
| Earnings from Continuing Operations | -21.42% | -21.53% | 5.96% | 15.51% | 22.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.42% | -21.53% | 5.96% | 15.51% | 22.65% |
| EBIT | -26.33% | -36.32% | -4.86% | 3.78% | 11.95% |
| EBITDA | -26.41% | -36.43% | -4.88% | 3.79% | 11.98% |
| EPS Basic | -29.72% | -28.75% | 2.38% | 14.34% | 23.25% |
| Normalized Basic EPS | -48.08% | -61.26% | -16.44% | -3.35% | 9.44% |
| EPS Diluted | -29.72% | -28.75% | 2.38% | 14.34% | 23.25% |
| Normalized Diluted EPS | -48.08% | -61.26% | -16.44% | -3.35% | 9.44% |
| Average Basic Shares Outstanding | -6.32% | -5.37% | -3.25% | -1.07% | 0.83% |
| Average Diluted Shares Outstanding | -6.32% | -5.37% | -3.25% | -1.07% | 0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |